Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.

Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON study for treating sickle cell disease (SCD), an inherited blood disorder.

Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...

Equities research analysts at Leerink Partnrs boosted their FY2024 earnings estimates for Beam Therapeutics in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M ...

Beam Therapeutics (BEAM – Research Report) received a Buy rating and a $37.00 price target from Bernstein analyst William Pickering today. The ...

Beam Therapeutics (BEAM) announced the company will encore data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease in ...

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company at the forefront of precision genetic medicines with a market capitalization of $1.87 billion, is navigating a critical juncture in its ...

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) has earned an average rating of “Moderate Buy” from the twelve ...

Cambridge, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing ...

CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...

Beam Therapeutics is set to present positive and significant data from the BEACON Phase 1/2 clinical trial of BEAM-101 at a major conference, enhancing visibility and credibility within the ...